U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

This was the stock's second consecutive day of gains.

Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending ...

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...